JP2019521156A - Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 - Google Patents

Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 Download PDF

Info

Publication number
JP2019521156A
JP2019521156A JP2019502063A JP2019502063A JP2019521156A JP 2019521156 A JP2019521156 A JP 2019521156A JP 2019502063 A JP2019502063 A JP 2019502063A JP 2019502063 A JP2019502063 A JP 2019502063A JP 2019521156 A JP2019521156 A JP 2019521156A
Authority
JP
Japan
Prior art keywords
seq
antibody
patient
binding fragment
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019502063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521156A5 (enExample
Inventor
ファッシュ，アンドレアス
オリバー，ジェイミー
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59677269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2019521156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2019521156A publication Critical patent/JP2019521156A/ja
Publication of JP2019521156A5 publication Critical patent/JP2019521156A5/ja
Priority to JP2022100449A priority Critical patent/JP2022126791A/ja
Priority to JP2023172063A priority patent/JP2024001125A/ja
Priority to JP2025058479A priority patent/JP2025102888A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019502063A 2016-07-19 2017-07-18 Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 Pending JP2019521156A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022100449A JP2022126791A (ja) 2016-07-19 2022-06-22 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2023172063A JP2024001125A (ja) 2016-07-19 2023-10-03 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2025058479A JP2025102888A (ja) 2016-07-19 2025-03-31 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364007P 2016-07-19 2016-07-19
US62/364,007 2016-07-19
PCT/IB2017/054333 WO2018015880A1 (en) 2016-07-19 2017-07-18 Methods of treating new-onset plaque type psoriasis using il-17 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022100449A Division JP2022126791A (ja) 2016-07-19 2022-06-22 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法

Publications (2)

Publication Number Publication Date
JP2019521156A true JP2019521156A (ja) 2019-07-25
JP2019521156A5 JP2019521156A5 (enExample) 2020-08-27

Family

ID=59677269

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019502063A Pending JP2019521156A (ja) 2016-07-19 2017-07-18 Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2022100449A Withdrawn JP2022126791A (ja) 2016-07-19 2022-06-22 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2023172063A Pending JP2024001125A (ja) 2016-07-19 2023-10-03 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2025058479A Pending JP2025102888A (ja) 2016-07-19 2025-03-31 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022100449A Withdrawn JP2022126791A (ja) 2016-07-19 2022-06-22 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2023172063A Pending JP2024001125A (ja) 2016-07-19 2023-10-03 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2025058479A Pending JP2025102888A (ja) 2016-07-19 2025-03-31 Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法

Country Status (6)

Country Link
US (2) US20190194311A1 (enExample)
EP (2) EP4477265A3 (enExample)
JP (4) JP2019521156A (enExample)
CN (1) CN109476733A (enExample)
ES (1) ES2992409T3 (enExample)
WO (1) WO2018015880A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023064023A (ja) * 2021-10-25 2023-05-10 良丹 孫 乾癬を治療／抑制するための医薬の製造における試薬の使用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2992409T3 (es) * 2016-07-19 2024-12-12 Novartis Ag Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
US20220267432A1 (en) * 2019-07-30 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Method for treating autoimmune disease by il-17 antagonist
EP3797779A1 (en) * 2019-09-30 2021-03-31 Servei de Salut de Les Illes Balears - Ibsalut Combined therapy comprising an inhibitor of interleukin-17 activity and a vitamin d receptor agonist
CA3162052A1 (en) * 2019-12-06 2021-06-10 Novartis Ag Methods of treating lichen planus using interleukin-17 (il-17) antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016103153A1 (en) * 2014-12-22 2016-06-30 Novartis Ag Pharmaceutical products and stable liquid compositions of il-17 antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
HUE039353T2 (hu) 2005-12-13 2018-12-28 Lilly Co Eli Anti-IL-17 ellenanyagok
CA2637166A1 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies for treating cancer
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
RU2539029C2 (ru) 2008-09-29 2015-01-10 Роше Гликарт Аг Антитела против интерлейкина 17 (ил-17) человека и их применение
NO2625199T3 (enExample) * 2010-10-08 2018-04-21
EP2791171A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
CA2897682C (en) 2013-02-08 2023-03-14 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2015022656A1 (en) 2013-08-15 2015-02-19 Novartis Ag Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
ES2992409T3 (es) * 2016-07-19 2024-12-12 Novartis Ag Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016103153A1 (en) * 2014-12-22 2016-06-30 Novartis Ag Pharmaceutical products and stable liquid compositions of il-17 antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIAMANT THACI; ANDREW BLAUVELT; KRISTIAN REICH; ET AL: "SECUKINUMAB IS SUPERIOR TO USTEKINUMAB IN CLEARING SKIN OF SUBJECTS WITH MODERATE TO 以下備考", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. VOL:73, NR:3, JPN5019006390, September 2015 (2015-09-01), US, pages 400 - 409, ISSN: 0004545931 *
RICHARD G LANGLEY; BONI E ELEWSKI; MARK LEBWOHL; ET AL: "SECUKINUMAB IN PLAQUE PSORIASIS - RESULTS OF TWO PHASE 3 TRIALS", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. VOL:371, NR:4, JPN5019006389, 24 July 2014 (2014-07-24), US, pages 326 - 338, XP055414280, ISSN: 0004716046, DOI: 10.1056/NEJMoa1314258 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023064023A (ja) * 2021-10-25 2023-05-10 良丹 孫 乾癬を治療／抑制するための医薬の製造における試薬の使用

Also Published As

Publication number Publication date
WO2018015880A1 (en) 2018-01-25
CN109476733A (zh) 2019-03-15
EP3487881A1 (en) 2019-05-29
EP4477265A2 (en) 2024-12-18
JP2022126791A (ja) 2022-08-30
JP2024001125A (ja) 2024-01-09
EP3487881B1 (en) 2024-08-21
JP2025102888A (ja) 2025-07-08
ES2992409T3 (es) 2024-12-12
EP4477265A3 (en) 2025-03-19
US20230303677A1 (en) 2023-09-28
US20190194311A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
US20250161443A1 (en) Methods of administering secukinumab
JP6554155B2 (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
US20230303677A1 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
JP7341996B2 (ja) Ｉｌ－１７アンタゴニストを用いて化膿性汗腺炎を治療すること
WO2018158741A1 (en) Psoriasis disease modification following long-term treatment with an il-17 antagonist
JP2019505516A (ja) インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
KR20220110512A (ko) 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법
HK40088403A (en) Methods of treating psoriasis using il-17 antagonists
HK40037862A (en) Methods of treating psoriasis using il-17 antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210922

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220301